The US Food and Drug Administration (FDA) has announced that starting on 1 October 2026, manufacturers must submit adverse ...
Global harmonization of CGT regulations could expedite access to innovative therapies by standardizing evaluation and regulatory processes. Only 20% of trials submitted to both the FDA and EMA had ...
AI and digital tools are shifting quality oversight in the pharmaceutical industry from retrospective testing to real-time, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results